farbivo blutein dye200
alfa instruments s.r.l. via silvio maurano snc 84048 castellabate taliansko -
farbivo blutein dye300
alfa instruments s.r.l. via silvio maurano snc 84048 castellabate taliansko -
farbivo blutein dye400
alfa instruments s.r.l. via silvio maurano snc 84048 castellabate taliansko -
farbivo blutein dye500
alfa instruments s.r.l. via silvio maurano snc 84048 castellabate taliansko -
aqumeldi
proveca pharma limited - enalapril (maleate) - zástava srdca - Činidlá pôsobiace na systém renín-angiotenzín - treatment of heart failure.
súprava ivd orion - testovacie súpravy microalbuminuria
orion diagnostica co., koivu - mankaan tie 6 b 02101 espoo fínsko -
lumoxiti
astrazeneca ab - moxetumomab pasudotox - leukémia, chlpatá bunka - antineoplastické činidlá - lumoxiti as monotherapy is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukaemia (hcl) after receiving at least two prior systemic therapies, including treatment with a purine nucleoside analogue (pna).
deltyba
otsuka novel products gmbh - delamanid - tuberkulóza, odolná voči viacerým liečivám - antimycobacterials - deltyba is indicated for use as part of an appropriate combination regimen for pulmonary multi-drug resistant tuberculosis (mdr-tb) in adults, adolescents, children and infants with a body weight of at least 10 kg when an effective treatment regimen cannot otherwise be composed for reasons of resistance or tolerability (see sections 4. 2, 4. 4 a 5. je treba vziať do úvahy oficiálne usmernenie o vhodnom používaní antibakteriálne agentov.
spectrila
medac gesellschaft fuer klinische spezialpraeparate mbh - asparagináza - prekurzorová bunková lymfoblastická leukémia-lymfóm - antineoplastické činidlá - spectrila je indikovaná ako súčasť protinádorovej kombinovanej liečby na liečbu akútna lymfoblastická leukémia (all) u pediatrických pacientov od narodenia do 18 rokov a dospelých.
elzonris
stemline therapeutics b.v. - tagraxofusp - lymphoma - antineoplastické činidlá - elzonris is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (bpdcn).